BIOMARKER:

KRAS mutation + STK11 mutation

C3 | Sensitive

D | Sensitive

C3 | Resistant

D | Resistant

Non Small Cell Lung Cancer

Lung Adenocarcinoma

bevacizumab + atezolizumab

KRAS mutation + STK11 mutation|Non Small Cell Lung Cancer|bevacizumab + atezolizumab

bevacizumab

KRAS mutation + STK11 mutation|Non Small Cell Lung Cancer|bevacizumab

pembrolizumab + BGB324

KRAS mutation + STK11 mutation|Lung Adenocarcinoma|pembrolizumab + BGB324

CI-1040

KRAS mutation + STK11 mutation|Non Small Cell Lung Cancer|CI-1040

pembrolizumab + quaratusugene ozeplasmid

KRAS mutation + STK11 mutation|Non Small Cell Lung Cancer|pembrolizumab + quaratusugene ozeplasmid

Immunotherapy

KRAS mutation + STK11 mutation|Non Small Cell Lung Cancer|Immunotherapy

KRAS mutation + STK11 mutation|Lung Adenocarcinoma|Immunotherapy

PD-L1 inhibitor

KRAS mutation + STK11 mutation|Non Small Cell Lung Cancer|PD-L1 inhibitor